Fig. 5

TRPM3 activity after co-modulation with nifedipine and ononetin. Data were obtained under whole-cell patch clamp conditions. a. A representative time-series of current amplitude at + 100 mV and − 100 mV showing the effect of 10 μΜ ononetin on ionic currents in the presence of nifedipine in isolated NK cells from HC. b. I–V before and after application of ononetin in a cell as shown in (a.). c. A representative time-series of current amplitude at + 100 mV and − 100 mV showing the effect of 10 μΜ ononetin on ionic currents in the presence of nifedipine in isolated NK cells CFS/ME patients. d. I–V before and after application of ononetin in a cell as shown in (c.). e. f. Scatter plots representing change of each current amplitude before and after ononetin application in all NK cells from HC and CFS/ME patients. Each cell represented as red lines had reduction in currents by ononetin. g. Table summarizing data for sensitive and insensitive cells to 10 μΜ ononetin in HC (N = 6; n = 25) compared to CFS/ME patients (N = 6; n = 23). Data are analysed with Fisher’s exact test. Abbreviations: CFS/ME, chronic fatigue syndrome/myalgic encephalomyelitis; HC, healthy controls; NK, natural killer; PregS, Pregnenolone sulfate; TRPM3, Transient Receptor Potential Melastatin 3